HC Wainwright&Co.:重申Nektar Therapeutics(NKTR.US)评级,由买入调整至买入评级,目标价由6.50美元调整至6.50美元。内克塔治疗(NKTR.US)公司简介:内克塔治疗是一家以研究为基础的生物制药公司,致力于在未满足医疗需求的领域发现和开发药物。其研究和开发的新研究药物包括肿瘤学,免疫学和病毒学治疗。该公司专注于使用新的化学方法来制造治疗癌症和自身免疫...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.